Vaxart, Inc.: management transactions · United States · SEC (Form 4)

About Vaxart, Inc.

Vaxart, Inc. is a U.S.-listed clinical-stage biotechnology company traded on NASDAQ under the ticker VXRT. Headquartered in South San Francisco, California, the company develops oral recombinant pill vaccines and is trying to offer a differentiated alternative to conventional injectable vaccines. From an equity perspective, Vaxart is best viewed as a development-stage biotech with a proprietary platform rather than a commercial-stage vaccine manufacturer; its valuation is therefore primarily driven by clinical data, partnership value, and the strength of its intellectual property. The company’s scientific roots are closely tied to Sean Tucker, Ph.D., Vaxart’s Founder and Chief Scientific Officer since February 2010. Vaxart’s core thesis is that oral vaccination may improve convenience, logistics, and potentially immune responses at mucosal surfaces, particularly in the gut. That strategy is important because mucosal immunity is a major area of interest in infectious disease prevention. The current leadership team is built around seasoned biotech and vaccine executives, with Steven Lo as Chief Executive Officer, reflecting a focus on clinical execution, business development, and capital allocation. Vaxart’s main programs are in COVID-19, norovirus, HPV, and influenza. The most advanced asset is its oral COVID-19 vaccine candidate, which is being evaluated in a phase 2b study of roughly 5,400 participants against an approved mRNA comparator. In November 2025, Vaxart announced an exclusive worldwide license and collaboration agreement with Dynavax Technologies for the COVID-19 oral vaccine candidate, including upfront consideration, an equity investment, and potential future milestone and royalty payments. This kind of transaction is important for investors because it can validate the platform while extending financial runway. The norovirus program is another key strategic asset. Throughout 2025, Vaxart reported positive clinical updates on its second-generation norovirus constructs, including data suggesting stronger antibody responses than its first-generation technology. The company has also highlighted preclinical and clinical work in HPV and flu, which could eventually broaden the platform beyond the lead infectious disease targets. However, Vaxart does not yet have a marketed product portfolio, so the investment case remains highly dependent on pipeline progression and trial readouts. In competitive terms, Vaxart’s differentiation lies not in scale, but in route of administration and platform design. It competes indirectly with large vaccine companies and, more broadly, with alternative prophylactic technologies. For investors in France, Belgium, and Switzerland, this is a high-risk, high-upside biotech story where execution, regulatory milestones, and partner interest matter far more than current revenues. Recent milestones include continued enrollment and follow-up in the phase 2b COVID-19 trial, the Dynavax licensing deal announced in late 2025, and multiple 2025–2026 updates supporting the company’s norovirus platform. Vaxart therefore remains a speculative but potentially disruptive U.S. NASDAQ-listed vaccine developer.